A phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma

被引：0
|
作者：
Ikeda, Masafumi [1 ]
Sung, Max W. [2 ]
Kudo, Masatoshi [3 ]
Kobayashi, Masahiro [4 ]
Baron, Ari D. [5 ]
Finn, Richard S. [6 ]
Kaneko, Shuichi [7 ]
Zhu, Andrew X. [8 ]
Kubota, Tomoki [9 ]
Kraljevic, Silvija [10 ]
Ishikawa, Kohei [9 ]
Siegel, Abby B. [11 ]
Kumada, Hiromitsu [4 ]
Young, Louise [12 ]
Okusaka, Takuji [13 ]
机构：
[1] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Chiba, Japan
[2] Tisch Canc Inst Mt Sinai, New York, NY USA
[3] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan
[4] Toranomon Gen Hosp, Dept Hepatol, Tokyo, Japan
[5] Pacific Hematol Oncol Associates, Calif Pacific Med Ctr, San Francisco, CA USA
[6] UCLA Med Ctr, David Geffen Sch Med, Losa Angeles, CA USA
[7] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Kanazawa, Ishikawa, Japan
[8] Harvard Univ, Massachusetts Gen Hosp, Boston, MA USA
[9] Eisai & Co Ltd, Tokyo, Japan
[10] Eisai Ltd, Hatfield, Herts, England
[11] Merck Co Inc, Kenilworth, NJ USA
[12] Eisai Australia Pty Ltd, Melbourne, Vic, Australia
[13] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
182
引用
收藏
页码：105 / 105
页数：1
相关论文
共 50 条
  • [21] A Phase IB/II Trial of Lenvatinib plus Pembrolizumab in Patients With Renal Cell Carcinoma
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Taylor, Matthew
    Dutcus, Corina
    Shumaker, Robert
    Schmidt, Emmett
    Stepan, Daniel E.
    Li, Di
    Young, Louise
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 153 - 153
  • [22] Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
    Chi-Jung Wu
    Pei-Chang Lee
    Ya-Wen Hung
    Chieh-Ju Lee
    Chen-Ta Chi
    I-Cheng Lee
    Ming-Chih Hou
    Yi-Hsiang Huang
    Cancer Immunology, Immunotherapy, 2022, 71 : 2631 - 2643
  • [23] Real-world experience of pembrolizumab plus lenvatinib in unresectable hepatocellular carcinoma in Taiwan.
    Wu, Chi-Jung
    Hung, Ya-Wen
    Lee, Pei-Chang
    Lee, ChiehJu
    Chen, Ming Huang
    Chao, Yee
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] A phase Ib study of lenvatinib plus pembrolizumab (LEN plus PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis
    Kudo, M.
    Finn, R.
    Ikeda, M.
    Zhu, A.
    Sung, M.
    Baron, A.
    Okusaka, T.
    Kobayashi, M.
    Kumada, H.
    Kaneko, S.
    Pracht, M.
    Meyer, T.
    Nagao, S.
    Saito, K.
    Mody, K.
    Dubrovsky, L.
    Llovet, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1401 - S1402
  • [25] Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
    Rizzo, Alessandro
    Dadduzio, Vincenzo
    Ricci, Angela Dalia
    Massari, Francesco
    Di Federico, Alessandro
    Gadaleta-Caldarola, Gennaro
    Brandi, Giovanni
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (04) : 371 - 378
  • [26] A phase 1b/2 trial of PXS-5505 combined with first line atezolizumab plus bevacizumab for treating patients with unresectable or metastatic hepatocellular carcinoma
    Burchard, Paul R.
    Ruffolo, Luis I.
    Ullman, Nicholas
    Dave, Yatee
    Belt, Brian A.
    Linehan, David C.
    Hernandez-Alejandro, Roberto
    Badri, Nabeel
    CLINICAL CANCER RESEARCH, 2022, 28 (17)
  • [27] Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002) a randomised, double-blind, phase 3 trial
    Llovet, Josep M.
    Kudo, Masatoshi
    Merle, Philippe
    Meyer, Tim
    Qin, Shukui
    Ikeda, Masafumi
    Xu, Ruocai
    Edeline, Julien
    Ryoo, Baek-Yeol
    Ren, Zhenggang
    Masi, Gianluca
    Kwiatkowski, Mariusz
    Lim, Ho Yeong
    Kim, Jee Hyun
    Breder, Valeriy
    Kumada, Hiromitsu
    Cheng, Ann-Lii
    Galle, Peter R.
    Kaneko, Shuichi
    Wang, Anran
    Mody, Kalgi
    Dutcus, Corina
    Dubrovsky, Leonid
    Siegel, Abby B.
    Finn, Richard S.
    LANCET ONCOLOGY, 2023, 24 (12): : 1399 - 1410
  • [28] Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study
    Yu, Zeyu
    Leng, Bin
    You, Ran
    Wang, Chendong
    Diao, Lingfeng
    Xu, Qingyu
    Yin, Guowen
    INVESTIGATIONAL NEW DRUGS, 2025, 43 (01) : 93 - 100
  • [29] Lenvatinib (LEN) plus pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.
    Lee, Chung-Han
    Shah, Amishi Yogesh
    Hsieh, James J.
    Rao, Arpit
    Pinto, Alvaro
    Bilen, Mehmet Asim
    Cohn, Allen Lee
    DiSimone, Christopher
    Shaffer, David R.
    Sarrio, Regina Girones
    Ribe, Sara Gunnestad
    Wu, Jane
    Schmidt, Emmett V.
    Kubiak, Peter
    Okpara, Chinyere
    Smith, Alan D.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma
    Bai, Yuxian
    Hu, Xichun
    Ren, Zhenggang
    Hisai, Takashi
    Yusa, Wataru
    Weng, Lidong
    Shiba, Sari
    Takase, Takao
    FUTURE ONCOLOGY, 2022, 18 (22) : 2413 - 2424
12345